{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:30Z","timestamp":1760747790531,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.026","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T16:57:38Z","timestamp":1657385858000},"page":"326-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-5415","authenticated-orcid":false,"given":"Javier","family":"Ros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ejca.2022.06.026_bib1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2022.06.026_bib2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-16-0297","article-title":"MET-driven resistance to dual EGFR and BRAF blockade may Be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer","volume":"6","author":"Pietrantonio","year":"2016","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.026_bib3","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ejca.2022.06.026_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E -mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ejca.2022.06.026_bib5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/PO.21.00107","article-title":"Targeting secondary and tertiary resistance to BRAF inhibition in BRAF V600E\u2013mutated metastatic colorectal cancer","volume":"5","author":"Akhoundova","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:38Z","timestamp":1760733518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492200377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":5,"alternative-id":["S095980492200377X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}